Portal de Periódicos da CAPES

Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment: A Case Report

2020; American College of Physicians; Volume: 173; Issue: 7 Linguagem: Inglês

10.7326/l20-0549

1539-3704

Eugene Brailovski, Richard B. Kim, David N. Juurlink,

Pancreatic and Hepatic Oncology Research

Letters6 October 2020Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment: A Case ReportEugene Brailovski, MD, CM, Richard B. Kim, MD, and David Juurlink, MD, PhDEugene Brailovski, MD, CMUniversity of Toronto, Toronto, Ontario, Canada (E.B., D.J.), Richard B. Kim, MDUniversity of Western Ontario, London, Ontario, Canada (R.B.K.), and David Juurlink, MD, PhDUniversity of Toronto, Toronto, Ontario, Canada (E.B., D.J.)Author, Article, and Disclosure Informationhttps://doi.org/10.7326/L20-0549 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Background: The sodium–glucose cotransporter-2 inhibitor canagliflozin is increasingly prescribed for the treatment of type 2 diabetes and is believed to have a low potential for drug interactions. Many patients treated with canagliflozin are also likely to receive a statin for primary or secondary prevention of cardiovascular events.Objective: To describe what we believe to be the first report of a patient with statin-induced myotoxicity after the initiation of canagliflozin.Case Report: A previously high-functioning 76-year-old Filipina woman presented to the hospital with new-onset muscle pain and difficulty ambulating. Her medical history included coronary artery disease, chronic kidney disease (stage 3B), ...References1. DeGorter MK, Tirona RG, Schwarz UI, et al. Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. Circ Cardiovasc Genet. 2013;6:400-8. [PMID: 23876492] doi:10.1161/CIRCGENETICS.113.000099 CrossrefMedlineGoogle Scholar2. Wang Q, Zheng M, Leil T. Investigating transporter-mediated drug-drug interactions using a physiologically based pharmacokinetic model of rosuvastatin. CPT Pharmacometrics Syst Pharmacol. 2017;6:228-238. [PMID: 28296193] doi:10.1002/psp4.12168 CrossrefMedlineGoogle Scholar3. Mamidi RNVS, Dallas S, Sensenhauser C, et al. In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin. Br J Clin Pharmacol. 2017;83:1082-1096. [PMID: 27862160] doi:10.1111/bcp.13186 CrossrefMedlineGoogle Scholar4. Das SR, Everett BM, Birtcher KK, et al. 2018 ACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2018;72:3200-3223. [PMID: 30497881] doi:10.1016/j.jacc.2018.09.020 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: University of Toronto, Toronto, Ontario, Canada (E.B., D.J.)University of Western Ontario, London, Ontario, Canada (R.B.K.)Disclosures: Authors have disclosed no conflicts of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L20-0549.Corresponding Author: David Juurlink, MD, PhD, Sunnybrook Health Sciences Centre, G Wing 106, 2075 Bayview Avenue, Toronto, ON M4N 3M5, Canada; e-mail, david.[email protected]on.ca.This article was published at Annals.org on 4 August 2020. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoRosuvastatin Myotoxicity After Starting Canagliflozin Treatment Rao N.V.S. Mamidi , Damayanthi Devineni , Don Sun , Yshai Yavin , and Norman Rosenthal Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment Ahmad Alamer , Charisse Te , and Maryam T. Fazel Metrics Cited bySafety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summaryComprehensive Review on the Bis–heterocyclic Compounds and their Anticancer EfficacyDrug–Drug Interaction of the Sodium Glucose Co-Transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting DataStatin-induced rhabdomyolysis in a 60-year-old woman with decompensated type 2 diabetes: a case reportMyopathy Associated With Statins and SGLT2 – A Review of LiteratureRosuvastatin Myotoxicity After Starting Canagliflozin TreatmentAhmad Alamer, PharmD, Charisse Te, MD, Maryam T. Fazel, PharmDRosuvastatin Myotoxicity After Starting Canagliflozin TreatmentRao N.V.S. Mamidi, PhD, Damayanthi Devineni, PhD, Don Sun, MD, Yshai Yavin, MBChB, Norman Rosenthal, MDSGLT2 inhibitors: a narrative review of efficacy and safetySide effects of insulin and other antihyperglycemic drugsStatin Treatment in Specific Patient Groups: Role for Improved Cardiovascular Risk MarkersCanagliflozin/rosuvastatin interaction 6 October 2020Volume 173, Issue 7Page: 585-587KeywordsAttentionBreast cancerDrug interactionsDrugsMyalgiaPolypeptidesProteinsResearch laboratoriesStatinsType 2 diabetes ePublished: 4 August 2020 Issue Published: 6 October 2020 Copyright & PermissionsCopyright © 2020 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...